Treats serious infections caused by susceptible anaerobic bacteria. ANDA 65442, held by Aurobindo Pharma. Clindamycin Hydrochloride.
As of Nov 16, 2026, ANDA 65442 (Clindamycin Hydrochloride), held by Aurobindo Pharma, was first approved by FDA on Aug 26, 2009, with 13 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Clindamycin hydrochloride capsules are indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin hydrochloride capsules are also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of colitis, as described in the BOXED WARNING, before selecting clindamycin, the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin).
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 26, 2009 | Original application | Approved | None posted |
| Clindamycin HydrochlorideEQ 150MG BASE · capsule;oral | Clindamycin Hydrochloride | Rx |
| Clindamycin HydrochlorideEQ 300MG BASE · capsule;oral | Clindamycin Hydrochloride | Rx |
| Aug 11, 2026 | Supplement 22Labeling · Standard review | Approved | None posted |
| Aug 11, 2026 | Supplement 24Labeling · Standard review | Approved | None posted |
| Aug 11, 2026 | Supplement 25Labeling · Standard review | Approved | None posted |
| May 9, 2023 | Supplement 17Labeling · Standard review | Approved | None posted |
| May 9, 2023 | Supplement 19Labeling · Standard review | Approved | None posted |
| Aug 19, 2019 | Supplement 8Labeling · Standard review | Approved | None posted |
| Aug 19, 2019 | Supplement 9Labeling · Standard review | Approved | None posted |
| Aug 19, 2019 | Supplement 11Labeling · Standard review | Approved | None posted |
| Aug 19, 2019 | Supplement 12Labeling · Standard review | Approved | None posted |
| Aug 19, 2019 | Supplement 15Labeling · Standard review | Approved | None posted |
| Jan 16, 2015 | Supplement 7Labeling · Standard review | Approved | None posted |
| Dec 27, 2011 | Supplement 3Labeling | Approved | None posted |
| May 20, 2010 | Supplement 1Labeling | Approved | None posted |
| Aug 26, 2009 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters